Benzinga | Oct 6, 2020 06:30AM EDT

HC Wainwright & Co. Maintains Buy on Corvus Pharmaceuticals, Raises Price Target to $12

HC Wainwright & Co. maintains Corvus Pharmaceuticals (NASDAQ:CRVS) with a Buy and raises the price target from $10 to $12.